**CORRELATION OF INFLAMMATION WITH STRUCTURAL AND FUNCTIONAL CHANGES IN THE RATS' PROSTATE GLAND WITH CHRONIC PROSTATITIS UNDER THE EXPOSURE OF CHONDROITIN SULPHATE**

N. M. Brechk a 1,2, V. V. Kozar 2, Ye. M. Koreniyeva 1, V. A. Bondarenko 1, O. V. Dolzhkova 1, N. O. Tkachenko 2, V. V. Borozenets 1, O. S. Protsenko 3, E. I. Zalubovskaya 4  

1 SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine  
2 National University of Pharmacy, Kharkiv, Ukraine  
3 V. N. Karazin Kharkiv National University, Kharkiv, Ukraine  
4 Kharkiv National Medical University, Kharkiv, Ukraine  
natalia01073@gmail.com

Chronic prostatitis is a common urological condition among men in the world. It has been shown that only 5 to 10% of patients with prostatitis have acute or chronic bacterial infection, while the majority of men with prostatitis (about 90-95%) have chronic pelvic disease without facts of infection (category III). For example, it has been found that in the United States, the prevalence of chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS) or nonbacterial chronic prostatitis ranges from 1.8% to 6.3%. With a prevalence of 1.8% equivalent to approximately 2 million cases, the total annual cost of treatment per patient is $ 4,397. In addition, young and middle-aged men first of all suffer from chronic prostatitis [1]. According to statistics, about 10% of urological patients in Ukraine are diagnosed with CP/CPPS [2].  

The etiology and pathogenesis of CP/CPPS remain substantially uncertain. To date, the triggers of chronic prostatitis CP/CPPS are considered chronic inflammation and/or hypothermia, the mutual influence of autoimmune, neuroendocrine and psychological factors.  

In patients with CP/CPPS in urine and prostate secretions, but not in sperm have been observed an increase in the number of leuko-
cytes compared with the control group of men without prostate disease. At the same time, the bacterial spectrum haven't had difference from the IC group. These studies confirm that the etiology and pathogenesis of CP/CPPS don’t depend on the microbial factor, but there is an inflammatory process [3]. Inflammation is associated with an increase in the concentration of pro-inflammatory cytokines (interleukin-1, tumor necrosis factor-a, interferon-γ) and the activity of autoimmunity (the reaction of T-cell proliferation to prostate antigens), intraprostatic urinary reflux, increased intraprostatic stress, etc. [4]. A large number of studies concerning the treatment of CP with the use of pharmacological drugs, physiotherapeutic, surgical and other procedures and the ambiguity of their results indicate that, unfortunately, there is still no consensus regarding the standards of treatment of the disease [5].

As far as inflammation is an important component of CP, in researches much attention is paid to inflammation, the effect of drugs on the molecular pathways of inflammation activation, on the regulation of the synthesis of pro- and anti-inflammatory cytokines, etc. [1].

At the same time, in our opinion, the role of another significant participant in inflammation, namely, connective tissue, is underestimated, since it is known that severe, permanent or prolonged trauma leads to dysregulation of connective tissue, because it is the environment where all stages of damage (inflammation, fibrosis, etc.) pass off. These processes, in turn, lead to dysfunction/loss of the functional state of the organ, and therefore the therapeutic reconstruction of the structure and function of the connective tissue of the prostatic gland can be another important strategy for the pharmacotherapy of CP/CPPS.

The aim of the work was to evaluate and compare changes of inflammation markers and histological structure of prostate tissue in rats with experimental chronic prostatitis under conditions of Chondroitin sulfate use.

MATERIALS AND METHODS

These experimental studies were carried out in compliance with the main rules of the European Convention on the Protection of Vertebrate Animals Used for Experimental and Scientific Purposes (Strasbourg, 1986) and the provisions of the General Ethical Principles for Animal Experiments (Kyiv, 2001) [6].

The experimental studies were carried on white mature male Wistar rats with weight of 270–370 g. Non-bacterial prostatitis was caused by local irrigation of the previously exposed surgical access to isthmus and ventral parts of the prostate for 5 seconds by an applicator for the wart removal Wartner®, the wounded surface was sewed in afterwards. All manipulations with animals were performed under ether anesthesia [7]. This model is characterized by necrotic-fibrotic changes as a result of direct cryo-traumatic damage to the prostate, hemodynamic disorders and inflammation [7].

To assess the anti-inflammatory and prostatoprotective properties, we used the introduction of the substance Chondroitin sulfate (manufactured by Sigma, USA) and the reference drug Prostaplant forte (manufactured by Schwabe, Germany). The drugs were administered three days before the simulation of cryo-traumatic prostatitis and within 11 days after cryotrauma. On the 12th day, animals were taken out of the experiment by rapid decapitation under light ether anesthesia. Animals were divided into the 5 groups (8 animals in each group): group 1 — intact control (IC); group 2 (control) — falsely operated rats (C FO) — small incision in the abdominal cavity in the area of the ventral part of the prostate; group 3 — control pathology (CP) (local irrigation of the anterior surface of the central part of the prostate (isthmus and ventral parts) within 5 seconds with an applicator for wart removal Wartner®; group 4 — control pathology + administration of Prostaplant forte (CP+PF) at a dose of 35 mg/kg; group 5 — control pathology + administration of Chondroitin sulfate substance (CP + CS) at a dose of 60 mg/kg.

The state of inflammation was assessed by the level of C-reactive protein (CRP), the number of leukocytes, the erythrocyte sedimentation rate in the blood, and during pharmacological correction. CRP was determined by the semiquantitative method of latex agglutina-
tion according to [8]. The sensitivity of the diagnosticum was 0.5 mg/l CRP. The number of leukocytes, ESR was determined by standard methods [7].

The state of the connective tissue was assessed according to the results of histological examination of the prostate, for this it was fixed in a 10% formalin solution, carried out using alcohols of increasing strength, and fill with celloidin-paraffin.

Histological preparations of the prostate after stained with hematoxylin and eosin was studied by microscopy (size, shape of acini, stroma and the integrity of the epithelial lining, etc.) [9]

Statistical processing of the obtained results was performed using parametric and non-parametric methods. As a result of the normal distribution, the arithmetic mean and its statistical error were calculated ($\bar{X} \pm S_{X}$); if the data were not consistent with the normal distribution, the median (Me), minimum and maximum data (min÷max) were calculated. Newman-Keuls method, nonparametric Wilcoxon–Mann–Whitney U-test and Kruskal–Wallis H-test were used to analyze differences. Critical level of significance was assumed to be equal to or less than 0.05 ($p \leq 0.05$).

### RESULTS AND THEIR DISCUSSIONS

It is known trauma cause inflammation. In our research, there was an increase in the number of leukocytes, ESR, the concentration of CRP appropriate to 1,8; 1,5 and 2 times compared with group of IC ($p \leq 0.05$) (Table 1) in the group of C FO animals. The combination of trauma and a cold agent (cryotrauma), as expected, was accompanied by a more expressed inflammatory process, which was characterized by an increase in the number of leukocytes and ESR compared to the group of falsely operated rats (1.5, 1.2 and 2 times, respectively, $p \leq 0, 05$).

In the group of animals receiving the studied drugs, a decrease in the manifestations of inflammation was observed not only in comparison with the group CP, but also in the group C FO, as evidenced by a decrease in leukocytosis, ESR and CRP ($p \leq 0,05$).

As mentioned earlier, the connective tissue is exactly the field of the pathological process development in the tissue, particularly inflammation. And the use of CS, which today is not classified as a drug for the treatment of prostatitis, turned out to be effective in reducing the manifestations of inflammation. The effect of CS on leukocytes, ESR, CRP haven’t had difference from the reference drug, and also slightly exceeded the average values in the CP + PF group.

### Peripheral blood indicators under the impact of drugs on model of the prostate cryotrauma and subject to pharmacological correction, ($n = 8$), ($\bar{X} \pm S_{X}$)

<table>
<thead>
<tr>
<th>Animal group</th>
<th>Leukocytes, $10^9 / l$</th>
<th>ESR, mm / hr</th>
<th>Me</th>
<th>min + max</th>
<th>$\bar{X} \pm S_X$</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC</td>
<td>9.88 ± 1.06</td>
<td>9.00 ± 0.95</td>
<td>2</td>
<td>2÷2</td>
<td>2.00 ± 0.00</td>
</tr>
<tr>
<td>C FO</td>
<td>18.00 ± 2.26$^1$</td>
<td>13.50 ± 1.20$^1$</td>
<td>4$^5$</td>
<td>2÷4</td>
<td>3.80 ± 0.70</td>
</tr>
<tr>
<td>CP</td>
<td>27.00 ± 1.86$^{(1)}$</td>
<td>16.25 ± 0.93$^{(2)}$</td>
<td>8$^0$</td>
<td>8÷8</td>
<td>8.00 ± 0.00</td>
</tr>
<tr>
<td>CP + PF</td>
<td>15.00 ± 1.32$^{(2)}$</td>
<td>11.50 ± 1.46$^{(0)}$</td>
<td>4$^0$</td>
<td>2÷4</td>
<td>3.30 ± 0.67</td>
</tr>
<tr>
<td>CP + CS</td>
<td>14.00 ± 1.46$^{(0)}$</td>
<td>10.25 ± 1.07$^{(0)}$</td>
<td>2$^{(0)}$</td>
<td>2÷4</td>
<td>2.70 ± 0.67</td>
</tr>
</tbody>
</table>

**Note:**

1) Statistically significant differences compared to IC group data, $p \leq 0.05$,

2) Statistically significant differences compared to C FO group data, $p \leq 0.05$,

3) Statistically significant differences compared to CP group data, $p \leq 0.05$,

4) Statistical differences with tendency to CP+PF group data, $p \leq 0.05$. 

---

**Table 1**
Therefore, inflammation, as one of the important pathogenetic factors of prostatitis, is positively influenced by both chondroprotective and prostateprotective drugs.

The results of histological examination of preparations of prostate showed that in the IC and C FO groups in the ventral lobe and in the area of the isthmus between the ventral lobules of the prostate, the acini of the prostate glands were predominantly rounded or partly oval in shape, their contours were well-defined, and the wall tension was good. The wall is lined with a single-layer cuboidal or simple columnar epithelium, which is in the part of the glands assembled in small folds. The nuclei of epithelial cells are basally located; at the lumen of the acini, eosinophilic secretions of different density are often visible. Paraprostatic tissues are not changed (Fig. 1).

12 days after cryotrauma in rats of the CP group in the prostate tissue, a specific productive inflammation have observed in the glandular tissue and in the surrounding paraprostatic tissue, collapse of the walls, their thickening in most acini, destruction of a part of the acini and thinning of their walls, distinct sinuosity, stretching of the lumen acini, death and necrosis of a part of acini, desquamation of degenerated cells, lime deposition, as well as edema of a loose fibrous stroma with hemorrhagic effusion.

The interacinar tissue is infiltrated with lymphocytes, histiocytes, plasma cells, hemorrhages, edema and protein effusion have seen in places (Fig. 2).

As seen in Fig. 3, the comparison drug Prostaplant Forte in the same mode of administration promoted a completely preservation

**Fig. 1.** The prostate gland of IC group: the normal state of the acini of the prostatic glands in the ventral lobe (a) and in the isthmus between the ventral lobules (b).
Hematoxylin-eosin. ×200.

**Fig. 2.** Rat prostate gland after cryotrauma:
- a — collapse of the walls, their thickening in most acini;
- b — destruction of part of the acini, thinning of the walls;
- c — expressive tortuosity of the contours, stretching of the lumen of the acini.
Hematoxylin-eosin. ×100.
of the state of a significant number of acini of the prostatic glands in the ventral lobe of the prostate, the disappearance or reduction of inflammation in the interacinar stroma and paroprostatic tissue. There was no edema and interacinar protein effusion.

At the same time, the structure of the acini in the isthmus between the ventral lobes of the prostate has not yet fully recovered, in some acini the wall was focal destroyed, stretching and thinning of the epithelial lining was track down, and the tortuosity of the acini contours was increased.

After the course of administration of the CS substance, the morphofunctional state of many prostatic glands of the investigated prostate zones improved in comparison with the group CP. There was no inflammatory response in the paroprostatic tissue and in the interacinar stroma in the overwhelming majority of rats. The state of acini of different types of prostatic glands is actually unchanged.

The structure of the acini in the isthmus between the ventral lobes of the prostate have not had difference from the IC group. However, there were still acini of the prostatic glands in the ventral zone of the prostate, which were characterized by increased size, increased tortuosity of the form, thinning or focal damage to the integrity of a small amount epithelial lining.

In this way, the results of the laboratory and histological studies in the conditions of simulating prostatopathy have been shown that markers of inflammation of the blood and prostate tissue have parallel unidirectional changes. Both drugs have a distinct anti-inflammatory effect and they are able to protect prostate tissue from destructive changes resulting from inflammation. The effectiveness of CS did not concede to the comparison drug Prostaplant forte, and was even partly more effective in normalizing the concentration of CRP and reconstruction of prostate tissue.

CONCLUSIONS

1. In experimental cryo-traumatic prostatitis prostatoprotector Prostaplant Forte and chondroprotector Chondroitin sulfate show anti-inflammatory properties, as evidenced by a decrease in the number of leukocytes and erythrocyte sedimentation rate, the concentration of C-reactive protein in the blood, and decrease destructive changes in the prostate tissue.
2. In terms of anti-inflammatory properties, the chondroprotector Chondroitin sulfate is not concede to the prostatoprotector Prostaplant Forte; but in terms of effectiveness to reconstruction of prostatic tissue and to decreasing the level of inflammation markers in the blood, it even slightly exceeds the effect of the reference drug.
3. These results indicate that the use of a combination of prostatoprotectors and drugs capable of affecting the metabolism and reconstruction of connective tissue is promising for the treatment of prostatitis.
За статистикою близько 10 % урологічних хворих в Україні мають діагноз хронічного простатиту/синдрому хронічного тазового болю, або абактеріального хронічного простатиту. Етіологія і патогенез залишаються значною мірою ще невизначеними, проте запалення є одним із тригерів цього стану, в який залучена і сполучна тканина.

Метою даного дослідження було оцінити та співставити зміни маркерів запалення та гістоструктури тканини простати у щурів із експериментальним хронічним простатитом в умовах застосування Хондроїтину сульфату. Експериментальна модель небактеріального простатиту була змодельована хірургічним доступом до передміхурової залози (ПЗ) та місцевим зрошуванням простати спреєм "Вартнер" протягом 5 секунд. Для оцінки противапальніх та простатопротекторних властивостей застосовували введення субстанції Хондроїтину сульфату препарату порівняння Простаплант форте, які починали вводити за три доби до моделювання простатиту та протягом 11 діб. Визначали стан запалення за концентрацією С-реактивного білка, кількістю лейкоцитів, швидкістю зсідання еритроцитів в крові. Стан сполучної тканини оцінювали за результатами гістологічного дослідження передміхурової залози. Встановлено, що в умовах моделювання простатопатії маркери запалення в крові та тканині простати мають паралельні однонаправлені зміни. Досліджені препарати мають противапальні властивості та зменшують деструктивні зміни в простаті. ХС не поступався за ефектом препарату порівняння Простаплант форте, і був навіть дещо ефективнішим за нормалізацією концентрації С-реактивного білка, кількістю лейкоцитів, швидкістю зсідання еритроцитів в крові. Стан сполучної тканини оцінювали за результатами гістологічного дослідження передміхурової залози. Встановлено, що в умовах моделювання простатопатії маркери запалення в крові та тканині простати мають паралельні однонаправлені зміни. Досліджені препарати мають противапальні властивості та зменшують деструктивні зміни в простаті. ХС не поступався за ефектом препарата. Встановлено, що в умовах моделювання простатопатії маркери запалення в крові та тканині простати мають паралельні однонаправлені зміни. Досліджені препарати мають противапальні властивості та зменшують деструктивні зміни в простаті. ХС не поступався за ефектом препарата. Встановлено, що в умовах моделювання простатопатії маркери запалення в крові та тканині простати мають паралельні однонаправлені зміни. Досліджені препарати мають противапальні властивості та зменшують деструктивні зміни в простаті. ХС не поступався за ефектом препарата.

Ключові слова: абактеріальний простатит, Хондроїтин сульфат, Простаплант фортекс, сполучна тканина, запалення.
CORRELATION OF INFLAMMATION WITH STRUCTURAL AND FUNCTIONAL CHANGES IN THE RATS’ PROSTATE GLAND WITH CHRONIC PROSTATITIS UNDER THE EXPOSURE OF CHONDROITIN SULPHATE

N. M. Brechka 1,2, V. V. Kozar 2, Ye. M. Korenieva 1, V. A. Bondarenko 1, O. V. Dolzhkova 2, N. O. Tkachenko 1, V. V. Borozenets 1, O. S. Protsenko 1, E. I. Zalubovskaya 2

1 SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
2 National University of Pharmacy, Kharkiv, Ukraine
3 V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
4 Kharkiv National Medical University, Kharkiv, Ukraine
natalia01073@gmail.com

According to statistics, about 10% of urological patients in Ukraine have diagnose as well chronic prostatitis/chronic pelvic pain syndrome, or non-bacterial chronic prostatitis. The etiology and pathogenesis continue to be substantially uncertain, but inflammation is one of the triggers that also involves connective tissue. The aim of the work was to evaluate and compare changes of inflammation markers and histological structure of prostate tissue in rats with experimental chronic prostatitis under conditions of Chondroitin sulfate use.

Non-bacterial prostatitis was caused by local irrigation of the previously exposed surgical access to isthmus and ventral parts of the prostate for 5 seconds by an applicator for the wart removal Wartner®, the wounded surface was sewed in afterwards. To assess the anti-inflammatory and prostatoprotective properties, we used the introduction of the substance Chondroitin sulfate (manufactured by Sigma, USA) and the reference drug Prostaplant forte (manufactured by Schwabe, Germany). The drugs were administered three days before the simulation of cryotraumatic prostatitis and within 11 days after cryotrauma. The state of inflammation was assessed by the level of C-reactive protein, the number of leukocytes, the erythrocyte sedimentation rate in the blood, and during pharmacological correction. The state of the connective tissue was assessed according to the results of histological examination of the prostate.

The results of the laboratory and histological studies in the conditions of simulating prostatopathy have shown that markers of inflammation of the blood and prostate tissue have parallel unidirectional changes. Both drugs have a distinct anti-inflammatory effect and they are able to protect prostate tissue from destructive changes resulting from inflammation. The effectiveness of Chondroitin sulfate did not concede to the comparison drug Prostaplant forte, and was even partly more effective in normalizing the concentration of C-reactive protein and reconstruction of prostate tissue. These results indicate that the use of a combination of prostatoprotectors and drugs capable of affecting the metabolism and reconstruction of connective tissue is promising for the treatment of prostatitis.

Keywords: non-bacterial prostatitis, Chodroitin sulfate, Prostaplant forte, connective tissue, inflammation.